OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
OMLYCLO ® (omalizumab-igec) is the first and only FDA-approved omalizumab biosimilar approved for all four indications of XOLAIR ® (omalizumab) and designated as interchangeable with XOLAIR; OMLYCLO ® will be available in 75 mg/0.5 mL, 150 mg/mL and...
Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis
ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with 34% receiving placebo, at Week 72. Singapore's Health Sciences Authority (HSA) has approved...
Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend
BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited...
Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
SHANGHAI, Sept. 3, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis
"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%[1] , [2]" "HELIOS-A and B provide strong clinical evidence supporting improved patient outcomes" SINGAPORE, Sept. 1, 2026 /PRNewswire/ --...
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
HONG KONG, Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global...
Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
Highlights: Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; Operational quality of core industries steadily improved, with industrial...
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
SHANGHAI, Aug. 14, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV...
72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803 Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment...
Baidu to Pursue Voluntary Conversion to Dual-Primary Listing on The Main Board of The Stock Exchange of Hong Kong Limited
BEIJING, July 16, 2026 /PRNewswire/ -- Baidu, Inc. ("Baidu" or the "Company") (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), a leading AI company with strong Internet foundation, today announced that the board of directors of the...